vs

Side-by-side financial comparison of California BanCorp \ CA (BCAL) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $45.9M, roughly 1.8× California BanCorp \ CA). California BanCorp \ CA runs the higher net margin — 35.8% vs -38.1%, a 73.8% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 0.8%). Over the past eight quarters, California BanCorp \ CA's revenue compounded faster (44.7% CAGR vs 24.8%).

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

BCAL vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.8× larger
PRCT
$83.1M
$45.9M
BCAL
Growing faster (revenue YoY)
PRCT
PRCT
+19.4% gap
PRCT
20.2%
0.8%
BCAL
Higher net margin
BCAL
BCAL
73.8% more per $
BCAL
35.8%
-38.1%
PRCT
Faster 2-yr revenue CAGR
BCAL
BCAL
Annualised
BCAL
44.7%
24.8%
PRCT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCAL
BCAL
PRCT
PRCT
Revenue
$45.9M
$83.1M
Net Profit
$16.4M
$-31.6M
Gross Margin
64.9%
Operating Margin
48.8%
-4.1%
Net Margin
35.8%
-38.1%
Revenue YoY
0.8%
20.2%
Net Profit YoY
-2.1%
-27.9%
EPS (diluted)
$0.50
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCAL
BCAL
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$45.9M
$76.4M
Q3 25
$45.2M
$83.3M
Q2 25
$44.3M
$79.2M
Q1 25
$44.8M
$69.2M
Q4 24
$45.5M
$68.2M
Q3 24
$38.1M
$58.4M
Q2 24
$22.2M
$53.4M
Net Profit
BCAL
BCAL
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$16.4M
$-29.8M
Q3 25
$15.7M
$-21.4M
Q2 25
$14.1M
$-19.6M
Q1 25
$16.9M
$-24.7M
Q4 24
$16.8M
$-18.9M
Q3 24
$-16.5M
$-21.0M
Q2 24
$190.0K
$-25.6M
Gross Margin
BCAL
BCAL
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
BCAL
BCAL
PRCT
PRCT
Q1 26
-4.1%
Q4 25
48.8%
-40.6%
Q3 25
48.3%
-27.8%
Q2 25
45.3%
-28.0%
Q1 25
52.8%
-39.7%
Q4 24
52.2%
-28.9%
Q3 24
-59.1%
-38.4%
Q2 24
1.3%
-50.3%
Net Margin
BCAL
BCAL
PRCT
PRCT
Q1 26
-38.1%
Q4 25
35.8%
-39.1%
Q3 25
34.7%
-25.7%
Q2 25
31.8%
-24.7%
Q1 25
37.6%
-35.8%
Q4 24
37.7%
-27.6%
Q3 24
-43.2%
-35.9%
Q2 24
0.9%
-48.0%
EPS (diluted)
BCAL
BCAL
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.50
$-0.54
Q3 25
$0.48
$-0.38
Q2 25
$0.43
$-0.35
Q1 25
$0.52
$-0.45
Q4 24
$0.54
$-0.34
Q3 24
$-0.59
$-0.40
Q2 24
$0.01
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCAL
BCAL
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$399.9M
$245.6M
Total DebtLower is stronger
$33.8M
$51.7M
Stockholders' EquityBook value
$576.6M
$347.7M
Total Assets
$4.0B
$487.1M
Debt / EquityLower = less leverage
0.06×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCAL
BCAL
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$399.9M
$286.5M
Q3 25
$559.2M
$294.3M
Q2 25
$430.1M
$302.7M
Q1 25
$439.2M
$316.2M
Q4 24
$388.2M
$333.7M
Q3 24
$614.4M
$196.8M
Q2 24
$104.7M
$214.1M
Total Debt
BCAL
BCAL
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$33.8M
$51.6M
Q3 25
$33.4M
$51.6M
Q2 25
$52.9M
$51.5M
Q1 25
$70.3M
$51.5M
Q4 24
$69.7M
$51.5M
Q3 24
$69.1M
$51.4M
Q2 24
$42.9M
$51.4M
Stockholders' Equity
BCAL
BCAL
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$576.6M
$365.9M
Q3 25
$564.7M
$380.3M
Q2 25
$547.6M
$385.8M
Q1 25
$531.4M
$389.2M
Q4 24
$511.8M
$402.2M
Q3 24
$498.1M
$241.2M
Q2 24
$293.2M
$251.8M
Total Assets
BCAL
BCAL
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$4.0B
$508.1M
Q3 25
$4.1B
$511.5M
Q2 25
$4.0B
$513.1M
Q1 25
$4.0B
$519.4M
Q4 24
$4.0B
$534.0M
Q3 24
$4.4B
$374.1M
Q2 24
$2.3B
$374.4M
Debt / Equity
BCAL
BCAL
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.06×
0.14×
Q3 25
0.06×
0.14×
Q2 25
0.10×
0.13×
Q1 25
0.13×
0.13×
Q4 24
0.14×
0.13×
Q3 24
0.14×
0.21×
Q2 24
0.15×
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCAL
BCAL
PRCT
PRCT
Operating Cash FlowLast quarter
$57.3M
Free Cash FlowOCF − Capex
$56.9M
FCF MarginFCF / Revenue
124.1%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$93.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCAL
BCAL
PRCT
PRCT
Q1 26
Q4 25
$57.3M
$-10.3M
Q3 25
$16.0M
$-6.6M
Q2 25
$13.4M
$-15.0M
Q1 25
$7.0M
$-17.0M
Q4 24
$50.3M
$-32.4M
Q3 24
$18.3M
$-18.8M
Q2 24
$309.0K
$-15.7M
Free Cash Flow
BCAL
BCAL
PRCT
PRCT
Q1 26
Q4 25
$56.9M
$-12.2M
Q3 25
$15.9M
$-9.5M
Q2 25
$13.4M
$-17.8M
Q1 25
$6.9M
$-18.8M
Q4 24
$49.7M
$-33.6M
Q3 24
$18.1M
$-19.0M
Q2 24
$171.0K
$-16.8M
FCF Margin
BCAL
BCAL
PRCT
PRCT
Q1 26
Q4 25
124.1%
-15.9%
Q3 25
35.1%
-11.4%
Q2 25
30.2%
-22.5%
Q1 25
15.3%
-27.2%
Q4 24
109.2%
-49.2%
Q3 24
47.5%
-32.6%
Q2 24
0.8%
-31.4%
Capex Intensity
BCAL
BCAL
PRCT
PRCT
Q1 26
Q4 25
0.8%
2.4%
Q3 25
0.2%
3.4%
Q2 25
0.1%
3.5%
Q1 25
0.2%
2.7%
Q4 24
1.2%
1.7%
Q3 24
0.5%
0.4%
Q2 24
0.6%
2.0%
Cash Conversion
BCAL
BCAL
PRCT
PRCT
Q1 26
Q4 25
3.49×
Q3 25
1.02×
Q2 25
0.95×
Q1 25
0.41×
Q4 24
3.00×
Q3 24
Q2 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCAL
BCAL

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons